Christopher U. Missling

A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer's disease therapy: Analysis of the blarcamesine (ANAVEX2‐73) Phase 2a clinical study

Harald Hampel, Coralie Williams, Adrien Etcheto et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions · 2020 · 80 citations · Full text

Medicine, Neurology, Pharmacology +17

ANAVEX®2-73 (blarcamesine), a Sigma-1 receptor agonist, ameliorates neurologic impairments in a mouse model of Rett syndrome

Walter E. Kaufmann, Jeffrey Sprouse, Nell Rebowe et al. · Pharmacology Biochemistry and Behavior · 2019 · 51 citations

Medicine, Neuroscience, Pharmacology +6

Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial

Stephen Macfarlane, Timo Grimmer, Ken Teo et al. · The Journal of Prevention of Alzheimer s Disease · 2025 · 41 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Effects of the sigma-1 receptor agonist blarcamesine in a murine model of fragile X syndrome: neurobehavioral phenotypes and receptor occupancy

Samantha T. Reyes, Robert M. J. Deacon, Scarlett G. Guo et al. · Scientific Reports · 2021 · 19 citations · Full text

Medicine, Neuroscience, Pharmacology +15

Metallkomplexe mit biologisch wichtigen Liganden, LXXXIV [1] Halbsandwich-Komplexe von Rhodium(III), Iridium(III), Cobalt(III), Ruthenium(II), Ruthenium(III) und Chrom(III) mit Aminosäureester-Liganden Metal Complexes with Biologically Important Ligands, LXXXIV [1] Half-Sandwich Complexes o f Rhodium(III), Iridium(III), Cobalt(III), Ruthenium(II), Ruthenium(III) and Chromium(III) with Amino Acid Ester Ligands

Ralph Bergs, Roland Krämer, Michael Maurus et al. · Zeitschrift für Naturforschung B · 1996 · 16 citations · Full text

Natural Sciences, Biochemistry, Chemistry +15